Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2020

22.01.2020 | Original Research

Pattern and Significance of Tumour Budding in Colorectal Carcinomas Using ITBCC Guidelines: a Low Resource Setting Practice Observation

verfasst von: Uchenna S. Ezenkwa, Gabriel O. Ogun, Oluwarotimi O. Bamiro, Mbwas I. Mashor, Clement A. Okolo, Omolade O. Adegoke, Olufemi J. Ogunbiyi

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the pattern and significance of tumour budding among colorectal carcinoma (CRC) Nigerian patients using the 2016 International Tumour Budding Consensus Conference (ITBCC) guidelines.

Methods

H&E-stained slides of resected CRC at the University College Hospital and a private laboratory, both in Ibadan, Nigeria, from January 2008 to December 2017 were reviewed. Patient age, gender, tumour size and location were obtained from the surgical pathology records. Tumours were graded and staged according to the 2010 WHO and the 2017 UICC protocols, respectively. Tumour budding was determined at × 20 objective lens magnification with a 20-mm eyepiece field number diameter. Descriptive, Mann-Whitney U and chi-square test statistics were applied using SPSS 20; p < 0.05 was considered significant.

Results

Ninety-six cases were included in this study. Fifty-one (53.1%) showed tumour budding. Tumour bud count was low (0–4) in 66 (68.8%), intermediate (5–9) in 12 (12.5%) and high (≥ 10) in 18 (18.8%) tumours. Four tumours had pT1 stage, 35 pT2, 37 pT3 and 20 pT4. Forty-three (44.8%) tumours were lymph node–positive, and 10 (10.4%) had metastasis. Patients’ age and tumour size distribution were similar in the tumour budding and non-budding groups (52.4 ± 17.1/58.5 ± 13.9 years and 6.6 ± 2.9/6.6 ± 2.8 cm, respectively). There was significant association between tumour budding and tumour grade (p < 0.008), pT stage (p < 0.000), lymphovascular permeation (p < 0.000), perineural invasion (p < 0.003) and nodal status (p < 0.034), but not with gender (p = 0.588), metastasis (p = 0.327) and TNM group-stage (p = 0.062).

Conclusion

Tumour budding frequency is high among our CRC patients and is associated with poorer prognostic factors.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Seigel RL, Torre LA, Jemal A. Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Bray F, Ferlay J, Soerjomataram I, Seigel RL, Torre LA, Jemal A. Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2.
Zurück zum Zitat Allemani C, et al. Global surveillance of cancer survival 1995–2009 : analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries ( CONCORD-2 ). Lancet. 2015;385(9972):977–1010.CrossRef Allemani C, et al. Global surveillance of cancer survival 1995–2009 : analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries ( CONCORD-2 ). Lancet. 2015;385(9972):977–1010.CrossRef
3.
Zurück zum Zitat Brierley JD, Gospodarowicz MK, Wittekind C. Colon and Rectum. In: TNM Classification of Malignant Tumours. 8th ed: Wiley Blackwell; 2017. p. 84–8. Brierley JD, Gospodarowicz MK, Wittekind C. Colon and Rectum. In: TNM Classification of Malignant Tumours. 8th ed: Wiley Blackwell; 2017. p. 84–8.
4.
Zurück zum Zitat Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma : time to take notice. Mod Pathol. 2012;25(10):1315–25.CrossRef Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma : time to take notice. Mod Pathol. 2012;25(10):1315–25.CrossRef
5.
Zurück zum Zitat Rogers AC, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer. 2016;115(7):831–40.CrossRef Rogers AC, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer. 2016;115(7):831–40.CrossRef
6.
Zurück zum Zitat Beaton C, Twine CP, Williams GL, Radcliffe AG. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Color Dis. 2013;15:788–97.CrossRef Beaton C, Twine CP, Williams GL, Radcliffe AG. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Color Dis. 2013;15:788–97.CrossRef
7.
Zurück zum Zitat Lugli A, Karamitopoulou E, Zlobec I. Tumour budding : a promising parameter in colorectal cancer. Br J Cancer. 2012;106(11):1713–7.CrossRef Lugli A, Karamitopoulou E, Zlobec I. Tumour budding : a promising parameter in colorectal cancer. Br J Cancer. 2012;106(11):1713–7.CrossRef
8.
Zurück zum Zitat De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer : what do we know and what can we do? Virchows Arch. 2016;468:397–408.CrossRef De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer : what do we know and what can we do? Virchows Arch. 2016;468:397–408.CrossRef
9.
Zurück zum Zitat Lugli A, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference ( ITBCC) 2016. Nat Publ Gr. 2017;30(9):1299–311. Lugli A, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference ( ITBCC) 2016. Nat Publ Gr. 2017;30(9):1299–311.
10.
Zurück zum Zitat Barel F, et al. Histopathological factors help to predict lymph node metastases more efficiently than extra-nodal recurrences in submucosa invading pT1 colorectal cancer. Sci Rep. 2019;9:1–12.CrossRef Barel F, et al. Histopathological factors help to predict lymph node metastases more efficiently than extra-nodal recurrences in submucosa invading pT1 colorectal cancer. Sci Rep. 2019;9:1–12.CrossRef
11.
Zurück zum Zitat Demir A, Alan O. Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment. World J Surg Oncol. 2019;6:1–8. Demir A, Alan O. Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment. World J Surg Oncol. 2019;6:1–8.
12.
Zurück zum Zitat Gonzalez RS, Cates JM, Washington K. Associations among histologic characteristics and patient outcomes in colorectal carcinoma with a mucinous component. Histopathology. 2019;74(3):406–14.CrossRef Gonzalez RS, Cates JM, Washington K. Associations among histologic characteristics and patient outcomes in colorectal carcinoma with a mucinous component. Histopathology. 2019;74(3):406–14.CrossRef
13.
Zurück zum Zitat Brockmoeller SF, et al. Predicting systemic spread in early colorectal cancer: can we do better? World J Gastroenterol. 2019;25(23):2887–97.CrossRef Brockmoeller SF, et al. Predicting systemic spread in early colorectal cancer: can we do better? World J Gastroenterol. 2019;25(23):2887–97.CrossRef
14.
Zurück zum Zitat Hamilton SR, et al. Tumours of the colon and rectum. In: WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 131–82. Hamilton SR, et al. Tumours of the colon and rectum. In: WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 131–82.
15.
Zurück zum Zitat IBM SPSS Statistics for Windows, version20. IBM Corp. New York: Armonk; 2011. IBM SPSS Statistics for Windows, version20. IBM Corp. New York: Armonk; 2011.
16.
Zurück zum Zitat Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer : tumor budding as oncotarget. Oncotarget. 2010;1(7):651–61.CrossRef Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer : tumor budding as oncotarget. Oncotarget. 2010;1(7):651–61.CrossRef
17.
Zurück zum Zitat Zhang Q, Wang L, Huang D, Xu M, Weng W, Ni S, et al. Pathological risk factors for lymph node metastasis in patients with submucosal invasive colorectal carcinoma. Cancer Manag Res. 2019;11:1107–14.CrossRef Zhang Q, Wang L, Huang D, Xu M, Weng W, Ni S, et al. Pathological risk factors for lymph node metastasis in patients with submucosal invasive colorectal carcinoma. Cancer Manag Res. 2019;11:1107–14.CrossRef
18.
Zurück zum Zitat Konishi T, et al. Poorly differentiated clusters predict colon cancer recurrence: an in-depth comparative analysis of invasive-front prognostic markers. Am J Surg Pathol. 2019;42(6):705–14.CrossRef Konishi T, et al. Poorly differentiated clusters predict colon cancer recurrence: an in-depth comparative analysis of invasive-front prognostic markers. Am J Surg Pathol. 2019;42(6):705–14.CrossRef
Metadaten
Titel
Pattern and Significance of Tumour Budding in Colorectal Carcinomas Using ITBCC Guidelines: a Low Resource Setting Practice Observation
verfasst von
Uchenna S. Ezenkwa
Gabriel O. Ogun
Oluwarotimi O. Bamiro
Mbwas I. Mashor
Clement A. Okolo
Omolade O. Adegoke
Olufemi J. Ogunbiyi
Publikationsdatum
22.01.2020
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-020-00365-4

Weitere Artikel der Ausgabe 3/2020

Journal of Gastrointestinal Cancer 3/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.